Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Akero Therapeutics, Inc. - Common Stock (NQ:AKRO)

53.51 -0.29 (-0.55%)
Streaming Delayed Price Updated: 11:38 AM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Akero Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Halper Sadeh LLC Investigates AKRO, CCRD, PBBK on Behalf of Shareholders
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD), PB Bankshares, Inc. (Nasdaq - PBBK), Air Lease Corporation (NYSE – AL)
From Brodsky & Smith LLC
Via GlobeNewswire
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE, AKRO, PCH, ATXS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD), PB Bankshares, Inc. (Nasdaq - PBBK), Air Lease Corporation (NYSE – AL)
From Brodsky & Smith LLC
Via GlobeNewswire
Omeros Catapults Almost 150% On A Surprise $2.1 Billion Deal With Novo Nordisk
Novo Nordisk is licensing exclusive global rights to the company's experimental treatment for rare blood and kidney diseases. 
Via Investor's Business Daily
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
From Kahn Swick & Foti, LLC
Via Business Wire
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
 
Via Benzinga
Wall Street Pulls Back as Earnings Season Kicks Off; PepsiCo, Delta, and Costco Defy the Trend
U.S. markets took a step back on Thursday, with the Dow and Nasdaq closing lower. Still, some heavyweights bucked the trend: PepsiCo, Delta Air Lines, and Costco all reported stronger-than-expected... 
Via Chartmill
Topics Stocks
Why Akero Therapeutics Stock Trounced the Market on Thursday
The biotech will soon have a new owner. 
Via The Motley Fool
Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today
Via Stocktwits
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates AKRO, CCRD, AL, PBBK on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD), PB Bankshares, Inc. (Nasdaq - PBBK), Air Lease Corporation (NYSE - AL)
From Brodsky & Smith LLC
Via GlobeNewswire
Tilray Brands Posts Upbeat Results, Joins Byrna Technologies, Delta Air Lines And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion
Novo Nordisk to buy Akero Therapeutics for up to $5.2 billion, adding EFX, a late-stage MASH treatment candidate, to its metabolic disease portfolio. 
Via Benzinga
Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $4.7 Billion Buyout
The deal follows Roche's plan to buy 89bio, another MASH-focused biotech company. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
AKRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akero Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Dow Futures Inch Up As Wall Street Awaits Jerome Powell’s Speech: TSLA, NVO, DAL, PEP Among Stocks To Watch
Via Stocktwits
Topics Economy Stocks
What’s Driving The Super Rally In Akero Shares On Thursday Morning?
Novo Nordisk is set to acquire the firm, and Akero’s shareholders will receive $54 per share in cash at closing in addition to a contingent value right. 
Via Stocktwits
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO
From Kahn Swick & Foti, LLC
Via GlobeNewswire
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH 
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics Inc (NASDAQ:AKRO) Reports Q2 2025 Earnings: Narrower Loss and Clinical Progress Drive Investor Optimism
Akero Therapeutics reports Q2 2025 results with narrower-than-expected loss, strong cash reserves, and promising clinical progress in MASH treatment. Stock gains 6.5% pre-market. 
Via Chartmill
Akero (AKRO) Q2 Loss Narrows 6%
Via The Motley Fool
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
AKERO THERAPEUTICS INC (NASDAQ:AKRO) - A Strong Technical Setup in Biotech
AKERO THERAPEUTICS (NASDAQ:AKRO) shows strong technicals with a perfect 10 rating and a high-quality breakout setup, making it a stock to watch for traders. 
Via Chartmill
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased
Jefferies thinks big pharma companies are "still on the hunt" for deals. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.